Skip to main content
FDA accepts Melinta's Baxdela under priority status
6/20/2019

A supplemental new drug application from Melinta Therapeutics for the use of Baxdela, or delafloxacin, in adult patients with community-acquired bacterial pneumonia, has been accepted by the FDA under priority review status. The agency set the PDUFA date of Oct. 24.

Full Story: